Literature DB >> 21798290

A potential role for monoclonal antibodies in prophylactic and therapeutic treatment of influenza.

Nicasio Mancini1, Laura Solforosi, Nicola Clementi, Donata De Marco, Massimo Clementi, Roberto Burioni.   

Abstract

The role of humoral response in the effective control of infection by influenza viruses is well known, but the protection is usually limited to the infecting or vaccinating isolate and to few related strains. Recent studies have evidenced the existence of B-cell epitopes broadly conserved among different influenza subtypes recognized by monoclonal antibodies endowed with unprecedented broad activity. In this review, all major monoclonal antibodies directed against different influenza virus proteins are reported and their potential in the design of new anti-influenza prophylactic or therapeutic strategies is discussed.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21798290     DOI: 10.1016/j.antiviral.2011.07.013

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  21 in total

1.  Bovine lactoferrin-derived peptides as novel broad-spectrum inhibitors of influenza virus.

Authors:  Maria Grazia Ammendolia; Mariangela Agamennone; Agostina Pietrantoni; Fabio Lannutti; Rosa Anna Siciliano; Beatrice De Giulio; Carla Amici; Fabiana Superti
Journal:  Pathog Glob Health       Date:  2012-03       Impact factor: 2.894

2.  Multiplexed screening of natural humoral immunity identifies antibodies at fine specificity for complex and dynamic viral targets.

Authors:  Krista M McCutcheon; Julia Gray; Natalie Y Chen; Keyi Liu; Minha Park; Stote Ellsworth; Ralph A Tripp; S Mark Tompkins; Scott K Johnson; Shelly Samet; Lenore Pereira; Lawrence M Kauvar
Journal:  MAbs       Date:  2014-01-08       Impact factor: 5.857

3.  Direct administration in the respiratory tract improves efficacy of broadly neutralizing anti-influenza virus monoclonal antibodies.

Authors:  Victor H Leyva-Grado; Gene S Tan; Paul E Leon; Mark Yondola; Peter Palese
Journal:  Antimicrob Agents Chemother       Date:  2015-05-04       Impact factor: 5.191

4.  Site-specific glycosylation profile of influenza A (H1N1) hemagglutinin through tandem mass spectrometry.

Authors:  Esteban Cruz; Joel Cain; Ben Crossett; Veysel Kayser
Journal:  Hum Vaccin Immunother       Date:  2017-11-17       Impact factor: 3.452

Review 5.  Molecular determinants of influenza virus pathogenesis in mice.

Authors:  Ram P Kamal; Jaqueline M Katz; Ian A York
Journal:  Curr Top Microbiol Immunol       Date:  2014       Impact factor: 4.291

Review 6.  Phage display-based strategies for cloning and optimization of monoclonal antibodies directed against human pathogens.

Authors:  Nicola Clementi; Nicasio Mancini; Laura Solforosi; Matteo Castelli; Massimo Clementi; Roberto Burioni
Journal:  Int J Mol Sci       Date:  2012-07-04       Impact factor: 6.208

Review 7.  Multiantibody strategies for HIV.

Authors:  Andrew Hiatt; Larry Zeitlin; Kevin J Whaley
Journal:  Clin Dev Immunol       Date:  2013-06-06

Review 8.  Molecular signatures of hepatitis C virus (HCV)-induced type II mixed cryoglobulinemia (MCII).

Authors:  Giuseppe Sautto; Nicasio Mancini; Massimo Clementi; Roberto Burioni
Journal:  Viruses       Date:  2012-11-08       Impact factor: 5.048

9.  Human monoclonal antibodies as a new class of antiinfective compounds.

Authors:  Roberto Burioni; Alois B Lang; J Donald Capra
Journal:  Clin Dev Immunol       Date:  2013-09-11

Review 10.  Influenza B-cells protective epitope characterization: a passkey for the rational design of new broad-range anti-influenza vaccines.

Authors:  Nicola Clementi; Elena Criscuolo; Matteo Castelli; Nicasio Mancini; Massimo Clementi; Roberto Burioni
Journal:  Viruses       Date:  2012-11-14       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.